Investing with Awareness is drawing investors attention to MINDCURE (MCUR – CSE). IWA did a management call recently with MINDCURE President and CEO, Kelsey Ramsden. On the call Kelsey shared her vision with IWA. It was exactly in line with the news the was announced today:
“We think it is important to give individuals options in building their mental wealth, both when they are engaged in psychedelic-assisted psychotherapy as well as when they are not and are simply seeking better mental performance.” – Kelsey Ramsden, MINDCURE President and CEO.
This recent announcement with SOMA Breath is significant and investors should pay attention to what MINDCURE is doing.
Equally as important is the very attractive price of MINDCURE in the fifty-cent range, compared to the monster cash balance of approximately $20 million and the obvious leadership strength of MINDCURE.
MINDCURE is deeply undervalued.
The SOMA breath partnership is a very smart by move by the CEO of MINDCURE.
IWA believes strongly that a combined natural approach at MINDCURE is essential for success.
IWA notes the following:
“The positive dynamic effects of deep breathing are well known and the astute team at MINDCURE are all over this. This is because with the indrawing breath, the deep inhalation, the mind is set positively and affirmatively; it is then taking advantage of the natural fact that the person’s life-force is being drawn upon. If, however, we consider what happens when breath is exhaled, we see the process is reversed. During the interval between the exhalation and the next inhalation it is the universal life-force which then flows into the man because he is then passive, whereas when inhaling he was active. Now this universal life-force, when it expresses itself in man, acts as a link with the universal spirit and demands physical existence. In other words, when the breath is let out and briefly held before it is indrawn again, there is a bridge to the higher consciousness of man. The bridge is there, but he must take advantage of it and usually he does not. If, during those few moments of pause, he turned his mind into meditation upon his true being, he would find it easier then than at other times; or if he did the same thing after having had an unexpected glimpse, he could retain the uplift of the glimpse for a longer period. Even the thought of considering and incorporating the power of the breath proves that MINDCURE knows what they are doing. The work of MINDCURE must incorporate the breath. Very smart Kelsey, very smart.”
See the complete news release by MINDCURE below:
MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM
VANCOUVER, BC, April 27, 2021
Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate psychedelic-assisted psychotherapy into their lives.
VANCOUVER, BC, April 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership and licensing agreement with SOMA Breath Inc. (“SOMA Breath”). The term breathwork refers to breathing exercise techniques that manipulate the depth and rate of breath, and SOMA Breath is a global school that combines ancient breathwork techniques based on pranayama with modern science.
MINDCURE will license SOMA Breath’s 21-day mental health-designed breathwork program and will also build a custom breathwork track targeted towards psychedelic-assisted psychotherapies, both within iSTRYM, its psychedelics digital therapeutics platform. SOMA’s breathwork programs have been proven to help patients manage stress and reduce anxiety, and have been shown to produce brainwave activity in patients comparable to the effect of psychedelics.1 MINDCURE intends to create opportunities for therapists and patients to utilize SOMA Breath breathwork programs to foster psychedelic-like experiences without the need for psychedelics themselves, while also enhancing the effectiveness of post-session integration for psychedelic-assisted psychotherapies.
With existing partnerships to develop technology integrations and custom services in place with Speak Ai, LUCID and now Soma Breath, MINDCURE is building iSTRYM into the go-to resource that therapists and patients will turn to for science-backed, personalized mental health support at scale. The Company anticipates a late July release of the beta version of the iSTRYM application and platform.
“We think it is important to give individuals options in building their mental wealth, both when they are engaged in psychedelic-assisted psychotherapy as well as when they are not and are simply seeking better mental performance,” said Kelsey Ramsden, MINDCURE President and CEO.“SOMA Breath’s validated techniques and protocols will enable therapists to design psychedelic-like treatments without the need for actual psychedelics, and also to enhance the effectiveness of post-session integration, which is a key area of focus for us within iSTRYM.”
“At SOMA Breath, we have seen firsthand the transformational power of breathwork, and are eager to bring our scientifically-validated program into iSTRYM for therapists and patients around the world, and to work alongside MINDCURE to further the connection between breathwork and psychedelic-like experiences,” saidNiraj Naik, the Founder and CEO of SOMA Breath.“We believe that the breath is the key to unlocking peak performance and also can serve an important role in the treatment of many debilitating mental health illnesses, and it can be accessed anywhere, by anyone, at any time.”
Dr. Jeff Tarrant, the founder of the Neuro Meditation Institute in Eugene, Oregon,2 studied the impact of SOMA Breath breathwork techniques on the brain, and then compared the results with available research on traditional psychedelics. The results showed that breathwork meditation is able to produce similar experiences to those of traditional psychedelics.3
- How breathwork can help to manage stress and anxiety
- Applied science for personal wellbeing
- Can the Breath be Psychedelic?
About SOMA Breath Inc.
SOMA Breath’s overall mission is to empower people with knowledge, tools, and techniques to make positive and lasting change in their lives. SOMA Breath techniques have the power to transform someone even down to a cellular level. SOMA Breath, considered as a whole, with its range of possible uses and applications, is a framework for total life transformation.
SOMA Breath is a complete holistic system of Pranayama techniques, which can be arranged into different sequences depending on the type of workshop you are attending as well as tailored to your specific needs. There is no one size fits all, and we take into account the fact that everyone is different and requires different breathing techniques depending on their needs. SOMA Therapeutic Breathwork techniques are the core Pranayama techniques that have the most scientific evidence to support their function.
About iSTRYM™ Digital Therapeutics
iSTRYM is a first-of-its-kind software application that optimizes the healing journey for both patients and clinicians — before, during, and after therapy sessions. iSTRYM enhances therapy by bringing together a variety of healing solutions, such as convenient user dashboards, integrative music, guided breathwork, intelligent language processing, secure data analysis, and more.
Offering real-world data in real-time, iSTRYM enables clinicians and their client’s access to personalized technology that provides AI-driven data insights for improved clinical outcomes. From mindful integrative content to a repository of world-class treatment plans, iSTRYM provides the best in psychedelic therapy software. iSTRYM drives personalized, quantified, and best-in-class outcomes in psychedelic therapy, making Mental Wealth™ accessible.
The Company also announces it has granted a total of 50,000 stock options to certain employees pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.
About Mind Cure Health (MINDCURE) Inc.
MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.
MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.
IWA Disclaimer – IWA is a shareholder of MCUR.
Statements which are not purely historical are forward-looking statements, including any statements regarding beliefs, plans, expectations, or intentions regarding the future. It is important to note that actual outcomes and the Company’s actual results could differ materially from those in such forward-looking statements. Risks and uncertainties include, but are not limited to, economic, competitive, governmental, environmental, and technological factors that may affect the Company’s operations, markets, products, and prices. Readers should refer to the risk disclosures outlined in the Company’s Management Discussion and Analysis of its audited financial statements filed with the British Columbia Securities Commission.
NEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.